CTLA4 and hepatocellular carcinoma: In the low-risk group, treatment with anti-CTLA4 and anti-PD-1, either in monotherapy or combination therapy, was also more likely to affect HCC patients (Figures 9(d)–9(f), p = 0.02, p = 0.0013, and p = 0.0019).